KalVista Pharmaceuticals, Inc. 4
4 · KalVista Pharmaceuticals, Inc. · Filed Nov 23, 2016
Insider Transaction Report
Form 4
Renzi David
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2016-11-21$7.84/sh+36,640$287,258→ 36,640 total - Tax Payment
Common Stock
2016-11-21$8.59/sh−33,454$287,477→ 3,186 total - Disposition from Tender
Common Stock
2016-11-21$8.59/sh−3,186$27,378→ 0 total - Exercise/Conversion
Stock Option (Right to Buy)
2016-11-21−36,640→ 0 totalExercise: $7.84Exp: 2023-06-06→ Common Stock (36,640 underlying)
Footnotes (2)
- [F1]The transactions reported in this Form 4 were completed pursuant to the consummation of the actions contemplated in that certain Share Purchase Agreement, dated as of June 15, 2016, by and among Carbylan, KalVista Pharmaceuticals Ltd. ("KalVista"), the shareholders of KalVista, and T. Andrew Crockett as the Seller Representative (the "Transaction"), and reflect a 14 to 1 reverse stock split completed immediately prior to the closing of the Transaction.
- [F2]The option is fully vested and exercisable.